Cargando…

CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors

BACKGROUND: High-grade serous ovarian carcinomas (HGSCs) are a heterogeneous subtype of epithelial ovarian cancers and include serous cancers arising in the fallopian tube and peritoneum. These cancers are now subdivided into homologous recombination repair (HR)-deficient and proficient subgroups as...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lu, Xue, He, Yaowu, Johnston, Rebecca L., Nanayakarra, Devathri, Sankarasubramanian, Sivanandhini, Lopez, J. Alejandro, Friedlander, Michael, Kalimutho, Murugan, Hooper, John D., Raninga, Prahlad V., Khanna, Kum Kum
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9769062/ https://www.ncbi.nlm.nih.gov/pubmed/36539830 http://dx.doi.org/10.1186/s13046-022-02570-4

Ejemplares similares

CX-5461 Enhances the Efficacy of APR-246 via Induction of DNA Damage and Replication Stress in Triple-Negative Breast Cancer
por: Makhale, Ashwini, et al.
Publicado: (2021)

Blockade of PDGFRβ circumvents resistance to MEK-JAK inhibition via intratumoral CD8(+) T-cells infiltration in triple-negative breast cancer
por: Kalimutho, Murugan, et al.
Publicado: (2019)

The metastasis suppressor RARRES3 as an endogenous inhibitor of the immunoproteasome expression in breast cancer cells
por: Anderson, Alison M., et al.
Publicado: (2017)

Cep55 overexpression promotes genomic instability and tumorigenesis in mice
por: Sinha, Debottam, et al.
Publicado: (2020)

GSK3-β Stimulates Claspin Degradation via β-TrCP Ubiquitin Ligase and Alters Cancer Cell Survival
por: Cabrera, Elisa, et al.
Publicado: (2019)

Curaxin CBL0137 Exerts Anticancer Activity via Diverse Mechanisms
por: Jin, Ming-Zhu, et al.
Publicado: (2018)

Exploring the Interaction of Curaxin CBL0137 with G-Quadruplex DNA Oligomers
por: Dallavalle, Sabrina, et al.
Publicado: (2021)

Targeting Features of Curaxin CBL0137 on Hematological Malignancies In Vitro and In Vivo
por: Fetisov, Timur I., et al.
Publicado: (2023)

Chemical Optimization of CBL0137 for Human African Trypanosomiasis Lead Drug Discovery
por: Singh, Baljinder, et al.
Publicado: (2023)

Enhanced dependency of KRAS‐mutant colorectal cancer cells on RAD51‐dependent homologous recombination repair identified from genetic interactions in Saccharomyces cerevisiae
por: Kalimutho, Murugan, et al.
Publicado: (2017)

CEP55 is a determinant of cell fate during perturbed mitosis in breast cancer
por: Kalimutho, Murugan, et al.
Publicado: (2018)

Marizomib suppresses triple-negative breast cancer via proteasome and oxidative phosphorylation inhibition
por: Raninga, Prahlad V., et al.
Publicado: (2020)

Effective inhibition of MYC-amplified group 3 medulloblastoma by FACT-targeted curaxin drug CBL0137
por: Wang, Jiajia, et al.
Publicado: (2020)

Insights into the Mechanism of Curaxin CBL0137 Epigenetic Activity: The Induction of DNA Demethylation and the Suppression of BET Family Proteins
por: Maksimova, Varvara, et al.
Publicado: (2023)

CBL0137 increases the targeting efficacy of Rovalpituzumab tesirine against tumour-initiating cells in small cell lung cancer
por: Lindner, Daniel J., et al.
Publicado: (2020)

EMBR-06. EFFECTIVE INHIBITION OF MYC-AMPLIFIFIED GROUP 3 MEDULLOBLASTOMA BY FACT-TARGETED CURAXIN DRUG CBL0137
por: Wang, Jiajia, et al.
Publicado: (2021)

MBRS-62. CURAXIN CBL0137 INHIBITS THE VIABILITY OF CANCEROUS CELLS IN PRE-CLINIC MODELS OF MYC-AMPLIFIED MEDULLOBLASTOMA
por: Wang, Jiajia, et al.
Publicado: (2020)

The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia Progression
por: Xiao, Lin, et al.
Publicado: (2022)

Curaxin CBL0137 eradicates drug resistant cancer stem cells and potentiates efficacy of gemcitabine in preclinical models of pancreatic cancer
por: Burkhart, Catherine, et al.
Publicado: (2014)

Anticancer activity of a Gold(I) phosphine thioredoxin reductase inhibitor in multiple myeloma
por: Sze, Jun Hui, et al.
Publicado: (2019)

The FACT-targeted drug CBL0137 enhances the effects of rituximab to inhibit B-cell non-Hodgkin’s lymphoma tumor growth by promoting apoptosis and autophagy
por: Lv, Yan, et al.
Publicado: (2023)

Targeting BRF2 in Cancer Using Repurposed Drugs
por: Rashidieh, Behnam, et al.
Publicado: (2021)

COMMD3 loss drives invasive breast cancer growth by modulating copper homeostasis
por: Hancock, Janelle L., et al.
Publicado: (2023)

EHMTI-0137. Headache as an initial clinical symptom of carotid artery dissection
por: Slankamenac, P, et al.
Publicado: (2014)

Phosphorylation of Exo1 modulates homologous recombination repair of DNA double-strand breaks
por: Bolderson, Emma, et al.
Publicado: (2010)

PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
por: Morgan, Robert D., et al.
Publicado: (2018)

Identifying and Overcoming Mechanisms of PARP Inhibitor Resistance in Homologous Recombination Repair-Deficient and Repair-Proficient High Grade Serous Ovarian Cancer Cells
por: Gomez, Miriam K., et al.
Publicado: (2020)

Guidelines for diagnosis and management of the cobalamin-related remethylation disorders cblC, cblD, cblE, cblF, cblG, cblJ and MTHFR deficiency
por: Huemer, Martina, et al.
Publicado: (2016)

Exploring the Control of PARP1 Levels in High-Grade Serous Ovarian Cancer
por: Raspaglio, Giuseppina, et al.
Publicado: (2023)

BRCA1 A-Complex fine tunes repair functions of BRCA1
por: Harris, Janelle L, et al.
Publicado: (2011)

Cep55 regulation of PI3K/Akt signaling is required for neocortical development and ciliogenesis
por: Rashidieh, Behnam, et al.
Publicado: (2021)

RNA-binding protein NONO contributes to cancer cell growth and confers drug resistance as a theranostic target in TNBC
por: Kim, Seong-Jin, et al.
Publicado: (2020)

Peptidyl-prolyl isomerization for cytokinetic abscission: Fold and cut
por: van der Horst, Armando, et al.
Publicado: (2012)

Complexities of pharmacogenomic interactions in cancer
por: Khanna, Kum Kum, et al.
Publicado: (2020)

Crizotinib and PARP inhibitors act synergistically by triggering apoptosis in high-grade serous ovarian cancer
por: Sahin, Irem Durmaz, et al.
Publicado: (2019)

Signaling to the Epigenome: New Insights into the Roles of Nuclear Signaling Kinases in the Context of the Immune System and Cancer
por: Lim, Pek Siew, et al.
Publicado: (2017)

Are estrogen receptor-positive breast cancers in BRCA1 mutation carriers sporadic?
por: Lakhani, Sunil R, et al.
Publicado: (2010)

PARP Inhibitors Display Differential Efficacy in Models of BRCA Mutant High-Grade Serous Ovarian Cancer
por: Dickson, Kristie-Ann, et al.
Publicado: (2021)

Phenethyl Isothiocyanate Enhances the Cytotoxic Effects of PARP Inhibitors in High-Grade Serous Ovarian Cancer Cells
por: Jia, Yaxun, et al.
Publicado: (2022)

Improving PARP inhibitor efficacy in high-grade serous ovarian carcinoma: A focus on the immune system
por: Bound, Nirashaa T., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_k8sln5f2dqbvoqhlfpjh0nu6ne